# First-in-human Study of VE303 in Healthy Adult Volunteers

> **NCT04236778** · PHASE1 · COMPLETED · sponsor: **Vedanta Biosciences, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** VE303
- **DRUG:** Oral Vancomycin

## Key facts

- **NCT ID:** NCT04236778
- **Lead sponsor:** Vedanta Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-28
- **Primary completion:** 2019-03-11
- **Final completion:** 2019-03-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04236778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04236778, "First-in-human Study of VE303 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04236778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*